Hackensack, NJ and Toronto, ON - May 31, 2022 - Champions Oncology, Inc. (Nasdaq: CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, and Cyclica Inc. ("Cyclica"), a neo-biotech with the vision to advance the most robust and sustainable drug discovery pipeline, announced today a therapeutic development partnership.

The partnership will combine two therapeutic targets identified and validated within Champions' Lumin platform with Cyclica's drug discovery platform to establish a new therapeutic program. The planned partnership will initiate with a single program focused on previously unexplored targets present in tumor indications such as non-small cell lung cancer, head and neck cancer, and other solid tumors. The partnership will also leverage the unique experimental platforms available at Champions to ensure rapid and efficient development towards clinical evaluation. Under the terms of this agreement, Champions will co-own the program with Cyclica and take lead in advancing the program, and, upon achievement of specified milestones and events, will be obligated to make milestone and royalty payments to Cyclica. Should Champions decide not to continue development, Cyclica has the option to carry forward the program in exchange for milestone and royalty payments to Champions.

Ronnie Morris, MD, President and CEO of Champions Oncology, said "We're excited to announce our first partnership in small molecule drug discovery and development, following two development partnerships with other companies involving large molecules. This partnership with Cyclica is a continued validation of the power of our experimental and digital research platforms. With deeply characterized datasets including our world-leading PDX models and Pharmaco-Pheno-Multi Omic (PPMO) workflows, we can better understand what drives growth and survival of a tumor. These specific targets have been interesting ones for Champions, and we are excited to establish a pipeline program in partnership with Cyclica."

Naheed Kurji, President and CEO of Cyclica, shares "Cyclica's unique ability to address low data targets combined with Champions' oncology-focused platform has groundbreaking therapeutic potential. Most importantly, by exploiting novel targets with strong disease linkage, we aspire to improve patient outcomes significantly."

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Champions Oncology Inc. published this content on 31 May 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 31 May 2022 12:40:10 UTC.